Company: MYGN
Filing Date: 2025-11-04
Form Type: 10-Q
Source: 0000899923-25-000112
Chunk: 23

Company: MYRIAD GENETICS INC
Filing Date: 2025-11-04
Form: 10-Q
Item: Part I, Item 1
Chunk 23
---
 Report on Form 10-K, including enhanced disaggregation of the effective tax rate reconciliation and income taxes paid by jurisdiction.ReclassificationsCertain prior period amounts have been reclassified to conform with the current period presentation. The reclassifications have no impact on the Company's total assets, total liabilities, stockholders' equity, net loss, or cash flows from operations.

9

2.REVENUE

The Company primarily generates revenue by performing molecular diagnostic testing. Revenue is recorded at the estimated transaction price. Control is transferred and revenue is recognized once test results are released to the healthcare provider and/or patient.The following table presents details regarding the composition of the Company’s total revenue by product type and by geographical region, either U.S. or rest of world (“RoW”):

Three Months Ended September 30,20252024(in millions)U.S.RoWTotalU.S.RoWTotalHereditary Cancer$81.8 $11.2 $93.0 $78.4 $12.1 $90.5 Tumor Profiling26.7 2.8 29.5 26.5 5.1 31.6 Prenatal44.5 — 44.5 43.4 0.1 43.5 Pharmacogenomics38.7 — 38.7 47.7 — 47.7 Total revenue$191.7 $14.0 $205.7 $196.0 $17.3 $213.3 

Nine months ended September 30,20252024(in millions)U.S.RoWTotalU.S.RoWTotalHereditary Cancer$241.8 $33.8 $275.6 $235.6 $34.5 $270.1 Tumor Profiling81.0 9.2 90.2 77.1 18.0 95.1 Prenatal141.2 0.2 141.4 131.7 0.5 132.2 Pharmacogenomics107.5 — 107.5 129.6 — 129.6 Total revenue$571.5 $43.2 $614.7 $574.0 $53.0 $627.0 In determining the transaction price, the Company includes an estimate of the expected amount of consideration to be received.